Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune checkpoint inhibitors: A United States population-level analysis

Published: 26 March 2021| Version 2 | DOI: 10.17632/8f3tfgbdjx.2
Contributors:
Shannon Wongvibulsin,
Vartan Pahalyants,
Mark Kalinich,
William Murphy,
Kun-Hsing Yu,
Feicheng Wang,
Steven Chen,
Kerry Reynolds,
Shawn Kwatra,
Yevgeniy Semenov

Description

Supplemental materials for manuscript titled: Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune checkpoint inhibitors: A United States population-level analysis

Files

Institutions

Harvard Medical School Department of Dermatology

Categories

Dermatology

License